Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), OpGen Inc (OPGN)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGNDResearch Report), OpGen Inc (OPGNResearch Report) and Galectin Therapeutics (GALTResearch Report) with bullish sentiments.

Ligand Pharma (LGND)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma, with a price target of $281. The company’s shares closed yesterday at $133.56, close to its 52-week low of $131.23.

Pantginis wrote:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $281 price target. Our target is based on sum of the parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 30 out of over 178 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -24.3% and a 19.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $225.33 average price target.

See today’s analyst top recommended stocks >>

OpGen Inc (OPGN)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OpGen Inc, with a price target of $6. The company’s shares closed yesterday at $0.90, close to its 52-week low of $0.76.

Selvaraju commented:

“Our price target is derived from a market value of the firm at $79M excluding debt. This includes a discounted cash flow analysis based enterprise value of $80M for the QuickFISH and AMR products, with a 15% discount rate and 2% terminal growth rate.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -23.7% and a 14.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on OpGen Inc is a Moderate Buy with an average price target of $6.

Galectin Therapeutics (GALT)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Galectin Therapeutics, with a price target of $12. The company’s shares closed yesterday at $4.92.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.6% and a 34.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on Galectin Therapeutics is a Moderate Buy with an average price target of $12.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.